%0 Journal Article
%T Effectiveness of brodalumab in achieving treatment satisfaction for patients with plaque psoriasis: The ProLOGUE study.
%A Imafuku S
%A Ohata C
%A Okubo Y
%A Tobita R
%A Saeki H
%A Mabuchi T
%A Hashimoto Y
%A Murotani K
%A Kitabayashi H
%A Kanai Y
%J J Dermatol Sci
%V 105
%N 3
%D Mar 2022
%M 35248465
%F 5.408
%R 10.1016/j.jdermsci.2022.02.007
%X <B>BACKGROUND: </B>Real-life evidence on the quality of treatment with brodalumab in patients with plaque psoriasis based on patient-reported outcomes remains limited.<BR><B>OBJECTIVE: </B>To assess the effectiveness of brodalumab in achieving treatment satisfaction for real-life Japanese patients with psoriasis.<BR><B>METHODS: </B>As part of a single-arm, open-label, multicenter, prospective study (ProLOGUE), Psoriasis Area and Severity Index (PASI) scores, body surface area (BSA), and Treatment Satisfaction Questionnaire for Medication-9 (TSQM-9) domain scores were assessed at baseline and Weeks 12 and 48 of brodalumab treatment. Patient Global Assessment (PtGA) scores were captured at Weeks 12 and 48.<BR><B>RESULTS: </B>Seventy-five patients were enrolled, of whom 73 received brodalumab. PASI scores and BSA significantly reduced from baseline at Weeks 12 and 48 (all P < 0.0001). Most (90%) patients felt the treatment was effective on the PtGA scale at Weeks 12 and 48. TSQM-9 domain scores significantly improved at Weeks 12 and 48 (all P < 0.0001). A PASI score of ≤ 2 was suggested as a treatment goal for biologic treatment of psoriasis from a receiver operating characteristic curve analysis, although some of the TSQM-9 domain scores did not improve in patients achieving this goal. No new safety signals were observed.<BR><B>CONCLUSIONS: </B>Treatment with brodalumab was associated with improved objective symptoms and satisfaction in Japanese patients with psoriasis. A PASI score of ≤ 2 as a goal for biologic treatment of psoriasis may be feasible, although achieving this PASI goal alone may be insufficient to clearly improve long-term patient satisfaction (Japan Registry of Clinical Trials identifier: jRCTs031180037).